Tube Pharmaceuticals

What Tube Pharmaceuticals does

Tube Pharmaceuticals is described in firmographic records as a privately held biopharmaceutical company focused on the development of cancer medicines, headquartered in Vienna, Austria, with a stated headcount of 1-10 employees. The company's stated web address is tubepharma.de, and its business model is positioned as for-profit. No products, drug candidates, pipeline assets, patents, trademarks, partnerships, scientific advisors, management team members, or funding rounds are disclosed in the input data.

The available source material beyond the firmographic record consists of a single captured page from the tubepharma.de URL, which is in fact a domain marketplace listing on domainname.de offering the domain for sale. The page contains no company information, product information, scientific content, or operational disclosures; it is a standard domain transfer/bid interface with payment and contact forms. This creates a material data-integrity gap: the only first-party web presence that could be retrieved for the company is a parked-for-sale landing page rather than a corporate website, scientific pipeline disclosure, or regulatory filing. No revenue, ownership structure, investors, founders, operating geographies beyond the Vienna headquarters, social media profiles, certifications, integrations, or AI/ML capabilities are recorded in the source data. As a result, the description above is bounded strictly to what the firmographic record and source IDs directly support; further claims about pipeline status, technology platform, go-to-market approach, or revenue mechanics cannot be made without speculation.

Name

Tube Pharmaceuticals

Website

https://tubepharma.de

Company type

Private

Headcount range

1–10 employees

Short description

Tube Pharmaceuticals is a privately held Vienna-based biopharmaceutical firm (1-10 employees) described as focused on developing cancer medicines; no products, pipeline, funding, or management team are disclosed in available source data, and the company's primary web address currently appears as a domain-for-sale listing.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Oncology drug development
• Biopharmaceutical research
• Cancer therapeutics
• Pharmaceutical development
• Drug discovery

Headquarters

HQ city

Vienna

HQ country

Austria

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Tube Pharmaceuticals is a biopharmaceutical company that develops cancer medicines. Its activity, as described in the available firmographic data, is centered on oncology drug research and development, with no specific commercialized products, named candidates, or pipeline details disclosed in the source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer medicines (oncology pipeline) Development of cancer medicines as a biopharmaceutical business; no specific drug candidates, indications, mechanisms of action, or commercialization stage are described in the source data.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• MorphoSys: German biopharmaceutical company (now under Novartis) developing antibody-based cancer therapies, headquartered in the same Central European region. Comparable as a larger European oncology biopharma incumbent that defines the strategic and competitive context for smaller regional developers.
• Genmab: Danish clinical-stage and commercial biotechnology company developing differentiated antibody therapeutics for cancer. Comparable as a European oncology biopharma, but at materially larger scale and broader scope than a 1–10 person developer.

Direct peers

• Oncopeptides: Swedish clinical-stage biopharmaceutical company developing targeted therapies for hematological cancers. Comparable as a small European oncology biopharma with a single-asset development focus and similar capital profile.
• Targovax: Norwegian clinical-stage biopharmaceutical company developing oncolytic virus immunotherapies for solid tumors. Comparable in scale and stage as a small European oncology developer with a single, focused therapeutic platform.
• Philogen: European (Italian/Swiss) clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, with a similar small-team R&D profile and oncology-only focus. Directly comparable as a small European developer of targeted oncology medicines.
• Nanobiotix: French clinical-stage biotechnology company developing nanoparticle-based therapies for cancer. Comparable as a small European oncology developer with a single, distinct therapeutic platform targeting high-value cancer indications.
• Adaptimmune: UK/US clinical-stage biopharmaceutical company developing engineered T-cell receptor therapies for solid tumors. Comparable as a development-stage oncology biopharma operating from a European base with a focused cancer pipeline.
• Innate Pharma: French immuno-oncology biopharmaceutical company developing first-in-class antibodies for cancer treatment. Comparable as a small-to-mid European oncology biopharma with a development-stage pipeline targeting high-value cancer indications.
• OSE Immunotherapeutics: French clinical-stage biopharmaceutical company developing immuno-oncology and immune-inflammation therapeutics. Comparable in scale and oncology focus as a small European biopharma pursuing development-stage cancer assets.

Regional players

• Helixor Heilmittel: Austrian/German pharmaceutical company developing mistletoe-based cancer therapies with a similar Vienna-area Central European footprint. Comparable as a regional oncology-focused biopharmaceutical developer serving primarily German-speaking markets.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/tube-pharmaceuticals-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tube Pharmaceuticals